# Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

> **NCT03530995** · PHASE1 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 73 (actual)

## Conditions studied

- Drug-drug Interaction
- Autoimmune Diseases
- Fibrotic Disease

## Interventions

- **DRUG:** Belumosudil
- **DRUG:** Itraconazole
- **DRUG:** Rabeprazole
- **DRUG:** Rifampicin
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT03530995
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-02-08
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03530995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03530995, "Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03530995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*